ACE2, the Counter-Regulatory Renin-Angiotensin System Axis and COVID-19 Severity.
Filippos Triposkiadis,Andrew Xanthopoulos,Grigorios Giamouzis,Konstantinos Dean Boudoulas,Randall C. Starling,John Skoularigis,Harisios Boudoulas,Efstathios K. Iliodromitis +7 more
Reads0
Chats0
TLDR
In this article, the relationship between ACE2 expression and function in the lungs and other organs and COVID-19 severity was discussed and the effect of ACE2 upregulation with renin-angiotensin-aldosterone system inhibitors (RAASi) counterbalances the risks due to counterregulatory RAS axis amplification.Abstract:
Angiotensin (ANG)-converting enzyme (ACE2) is an entry receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19). ACE2 also contributes to a deviation of the lung renin-angiotensin system (RAS) towards its counter-regulatory axis, thus transforming harmful ANG II to protective ANG (1-7). Based on this purported ACE2 double function, it has been put forward that the benefit from ACE2 upregulation with renin-angiotensin-aldosterone system inhibitors (RAASi) counterbalances COVID-19 risks due to counter-regulatory RAS axis amplification. In this manuscript we discuss the relationship between ACE2 expression and function in the lungs and other organs and COVID-19 severity. Recent data suggested that the involvement of ACE2 in the lung counter-regulatory RAS axis is limited. In this setting, an augmentation of ACE2 expression and/or a dissociation of ACE2 from the ANG (1-7)/Mas pathways that leaves unopposed the ACE2 function, the SARS-CoV-2 entry receptor, predisposes to more severe disease and it appears to often occur in the relevant risk factors. Further, the effect of RAASi on ACE2 expression and on COVID-19 severity and the overall clinical implications are discussed.read more
Citations
More filters
Journal ArticleDOI
Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets.
Masoumeh Farahani,Zahra Niknam,Leila Mohammadi Amirabad,Nasrin Amiri-Dashatan,Mehdi Koushki,Mohadeseh Nemati,Fahima Danesh Pouya,Mostafa Rezaei-Tavirani,Yousef Rasmi,Lobat Tayebi +9 more
TL;DR: In this article, a review of the possible mechanisms of the host response following SARS-CoV-2 infection and surveyed current research conducted by in-vitro, in vivo and human observations, as well as existing suggestions.
Journal ArticleDOI
Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets
TL;DR: In this paper , a review of the possible mechanisms of the host response following SARS-CoV-2 infection and surveyed current research conducted by in vitro, in vivo and human observations, as well as existing suggestions.
Journal ArticleDOI
A Natural Plant Source-Tea Polyphenols, a Potential Drug for Improving Immunity and Combating Virus
TL;DR: TP can improve the disorder of flora, reduce the occurrence of cytokine storm, improve immunity, and prevent COVID-19 infection, and may be regarded as a potential and valuable source of new antiviral drugs with high efficiency and low toxicity.
Journal ArticleDOI
Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern
A. Chaouat,Ilija Brizić,Paola Kucan Brlic,Nofar Atari,L. Kliker,Orit Alfi,Michal Mandelboim,Dana G. Wolf,Laith Tafish,Inbal Kol,Stipan Jonjić,Ofer Mandelboim +11 more
TL;DR: Wang et al. as mentioned in this paper developed a specific antibody against human ACE2 named hACE2.16, an anti-ACE2 antibody that recognizes and blocks ACE2-RBD binding without affecting ACE2 enzymatic activity.
Journal ArticleDOI
Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic
Wolfgang Sipos,Southgate, Jack +1 more
TL;DR: In this article , the authors summarize the latest insights into the complexity and interplay of the counter-regulatory RAS axis in hypertension, highlight the pathophysiological functions of ACE2, a multifunctional molecule linking hypertension and COVID-19, and discuss the function and therapeutic potential of targeting this counterregulatory rAS axis to prevent and treat hypertension in the context of the current COVID19 pandemic.
References
More filters
Journal ArticleDOI
A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry.
Yanwen Chen,Yanwen Chen,Travis Lear,John Evankovich,Mads Breum Larsen,Bo Lin,Irene Alfaras,Jason R. Kennerdell,Laura Salminen,Daniel P. Camarco,Karina C. Lockwood,Ferhan Tuncer,Jie Liu,Michael M. Myerburg,John F. McDyer,Yuan Liu,Toren Finkel,Bill B. Chen +17 more
TL;DR: In this paper, the authors identify small molecules that reduce surface expression of TMPRSS2 using a library of 2,560 FDA-approved or current clinical trial compounds and identify homoharringtonine and halofuginone as the most attractive agents.
Journal ArticleDOI
COVID-19 and cancer registries: learning from the first peak of the SARS-CoV-2 pandemic.
Alvin J.X. Lee,Karin Purshouse +1 more
TL;DR: In this article, the authors collated the evidence from national and international studies and focus on the risk factors for patients with solid cancers and the contribution of systemic anti-cancer treatments (SACT-chemotherapy, immunotherapy, targeted and hormone therapy) to outcomes following SARS-Cov-2 infection.
Journal ArticleDOI
COVID-19 and the Renin-Angiotensin System.
TL;DR: A coronavirus disease leading to severe acute respiratory syndrome (SARS) started in China and has become a pandemic and the responsible virus has been designated SARS-CoV-2, a mostly membrane-bound homologue of angiotensin-converting enzyme (ACE) that has generated great interest in the interaction between COVID-19 and the renin-angiotens in system (RAS).
Journal ArticleDOI
Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney.
Xiao Jiang,James Eales,David Scannali,Alicja Nazgiewicz,Priscilla R. Prestes,Michelle C. Maier,Matthew Denniff,Xiaoguang Xu,Sushant Saluja,Eddie Cano-Gamez,Wojciech Wystrychowski,Monika Szulińska,Andrzej Antczak,Sean G. Byars,Damian Skrypnik,Maciej Glyda,Robert Król,Joanna Zywiec,Ewa Zukowska-Szczechowska,Louise M Burrell,Adrian S. Woolf,Adrian S. Woolf,Adam Greenstein,Adam Greenstein,Paweł Bogdański,Bernard Keavney,Bernard Keavney,Andrew P. Morris,Anthony M. Heagerty,Anthony M. Heagerty,Bryan Williams,Stephen Harrap,Gosia Trynka,Nilesh J. Samani,Nilesh J. Samani,Tomasz J. Guzik,Tomasz J. Guzik,Fadi J. Charchar,Fadi J. Charchar,Fadi J. Charchar,Maciej Tomaszewski,Maciej Tomaszewski +41 more
TL;DR: Neither hypertension nor antihypertensive treatment is likely to alter the expression of the key entry receptor for SARS-CoV-2 in the human kidney, and renal abundance of ACE2 is positively associated with a biochemical index of kidney function.
Journal ArticleDOI
Therapeutic Targeting of Cancer Stem Cells via Modulation of the Renin-Angiotensin System
TL;DR: It is suggested that the presence of components of the RAS in CSCs could offer an avenue for therapeutic targeting using RAS modulators, and a systems approach using traditional RAS inhibitors in combination with inhibitors of bypass loops ofThe RAS and other signaling pathways that converge on the R AS may offer a novel therapeutic approach to cancer treatment.